What is Precipio?
Precipio, Inc., established in 2011 and headquartered in New Haven, Connecticut, operates as a specialized diagnostics firm dedicated to mitigating cancer misdiagnosis. The company fosters collaborations with premier academic institutions engaged in cancer research, diagnostics, and treatment. Through these partnerships, Precipio offers high-caliber pathology services and diagnostic insights, providing physicians and patients with precise, expert-validated diagnostic information to support informed clinical decisions and improve patient outcomes. The company's strategic focus on accuracy and expert-driven analysis positions it as a key player in the precision medicine landscape.
How much funding has Precipio raised?
Precipio has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Precipio
PPP
Public-Private Partnership
What's next for Precipio?
With its large-scale late-stage funding context, Precipio is poised for significant expansion and further development of its diagnostic platform. The recent strategic investment suggests a strong validation of its business model and market potential. Future initiatives are likely to involve scaling operations, enhancing technological capabilities, and potentially broadening its network of academic and clinical partnerships. This capital infusion will be instrumental in solidifying Precipio's position in the competitive diagnostics market and advancing its mission to combat cancer misdiagnosis.
See full Precipio company page
